FMR LLC reports 14.9% stake in TENAX

TENAX THERAPEUTICS INC reports that FMR LLC beneficially owns 3,942,373 shares of Common Stock, representing 14.9% of the class as of 06/30/2026.

Rhea-AI Filing Summary

TENAX THERAPEUTICS INC reports that FMR LLC beneficially owns 3,942,373 shares of Common Stock, representing 14.9% of the class as of 06/30/2026. The filing states the shares are held with sole dispositive power and identifies Abigail P. Johnson in a related capacity.

Insights

Institutional Ownership Analyst

FMR LLC holds a large, disclosed passive stake in TENAX.

FMR LLC reports beneficial ownership of 3,942,373 shares or 14.9% of common stock as of 06/30/2026. The schedule classifies holdings under Schedule 13G style passive disclosure rather than an activist 13D.

Filing notes sole dispositive power and identifies a related person, Abigail P. Johnson, for voting/dispositive relationships; cash‑flow treatment and any plans to trade are not stated in the excerpt.

Corporate Governance Specialist

Disclosure uses a power of attorney and exhibits to clarify authority.

The filing is signed under a Power of Attorney effective April 13, 2026, and references Exhibit 99 and Exhibit 24 for subsidiary/classification details. This indicates formal delegation for reporting and possible subsidiary reporting obligations.

Investors can expect subsequent exhibits to show the internal allocation or the specific subsidiary if applicable; the schedule itself lists the ownership figures and voting/dispositive powers.

Key Figures

Reporting form: Schedule 13G Beneficial ownership: 3,942,373 shares Percent of class: 14.9% +1 more

4 metrics

Reporting form Schedule 13G Ownership disclosure filing

Beneficial ownership 3,942,373 shares Amount beneficially owned as of 06/30/2026

Percent of class 14.9% Percent of common stock as reported

CUSIP 88032L605 Tenax common stock identifier

Key Terms

Schedule 13G, Beneficial ownership, Power of Attorney, 13d-1(k)(1) agreement

4 terms

Schedule 13G regulatory

"Item 1. Name of issuer: TENAX THERAPEUTICS INC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership financial

"Item 4. Ownership (a) Amount beneficially owned: 3942373.00"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Power of Attorney legal

"Duly authorized under Power of Attorney effective as of April 13, 2026"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

13d-1(k)(1) agreement regulatory

"Please see Exhibit 99 for 13d-1(k) (1) agreement."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in TENX?

FMR LLC reports beneficial ownership of 3,942,373 shares, equal to 14.9% of common stock as of 06/30/2026. The filing lists sole dispositive power over these shares and includes related signing authority details.

Does the Schedule 13G filing show who controls voting or sale decisions for TENX shares?

The filing states FMR LLC has sole dispositive power over 3,942,373 shares. It also shows sole voting power figures on the cover and names Abigail P. Johnson in the cover relationships and signature context.

What documents accompany the TENX Schedule 13G for more detail?

The filing references Exhibit 99 for a 13d-1(k)(1) agreement and incorporates a Power of Attorney via Exhibit 24. Those exhibits provide subsidiary identification and signature authority details mentioned in the schedule.

What date does the TENX ownership figure reference?

The ownership figure is presented with an as-of date of 06/30/2026. The Schedule 13G cover and Item 4 bind the 3,942,373 shares and the 14.9% percentage to that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 10:11 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TENAX THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

88032L605

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,942,373.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,942,373.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,942,373.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.9 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,942,373.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,942,373.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TENAX THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 101 GLEN LENNOX DRIVE,SUITE 300,CHAPEL HILL,NC,US,27517
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 88032L605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3942373.00
(b)	Percent of class: 14.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 3942373.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TENAX THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of TENAX THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	07/07/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	07/07/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.